Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy

Youn, Jong Chan; Kim, Darae; Kim, Kyung An; Kim, Jin‐Jin; Kim, In Cheol; Lee, Hye Sun; Choi, Jin‐Oh; Jeon, Eun‐Seok; Nishihara, K.; Kransdorf, E.; Chang, D.; Kittleson, M.; Patel, Jignesh; Ramzy, Danny; Esmailian, F.; Kobashigawa, Jon A.

doi:10.1111/ajt.17186

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from rejection or primary graft dysfunction, several challenges still follow heart transplantation related to the efficacy or safety of immunosuppression, such as infection, late graft dysfunction, cardiac allograft vasculopathy, and malignancy [ 10 , 82 , 83 ]. Because the clinical course differs completely after transplantation, appropriate patient selection is crucial.…”

Section: Heart Transplantationmentioning

confidence: 99%

Advanced heart failure: a contemporary approach

Park¹,

Kang²

2023

Korean J Intern Med

View full text Add to dashboard Cite

Advanced heart failure (HF) is defined as the persistence of severe symptoms despite the use of optimized medical, surgical, and device therapies. These patients require timely advanced treatments, such as heart transplantation or long-term mechanical circulatory support (MCS). Inotropic agents are often used to reduce congestion and increase cardiac output, while renal replacement therapy may be beneficial if necessary. Cardiac resynchronization therapy has clear benefits in patients with HF with reduced ejection fraction, particularly with left bundle branch block (QRS duration > 130 ms). The role of implantable cardioverter-defibrillators in advanced HF patients requires further investigation considering the introduction of novel HF medications. In selected patients with significant secondary mitral regurgitation, transcatheter edge-to-edge repair can help delay heart transplantation or long-term MCS. In later stages, the appropriateness of heart transplantation should be evaluated, and the use of short- or long-term MCS may be considered. A multidisciplinary HF management program is crucial for patients with advanced HF. Recent treatment advances, including drugs, devices, and MCS, have broadened the options available to patients with advanced HF and this trend is expected to continue.

show abstract

Section: Heart Transplantationmentioning

confidence: 99%